Nermeen Elbakary | Biochemistry | Best Researcher Award

Published on by Environmental Scientists

Assoc. Prof. Dr. Nermeen Elbakary | Biochemistry | Best Researcher Award

Associate professor of Biochemistry | Egyptian Atomic Energy Authority | Egypt

Dr. Nermeen Mohamed Sayed Ahmed Badr Elbakary is an accomplished biochemist and associate professor in the Radiation Biology Department at the National Centre for Radiation Research and Technology (NCRRT), Atomic Energy Authority, Cairo, Egypt. With extensive experience in cancer biology, molecular genetics, and radiation effects, she has led numerous investigations on therapeutic resistance, radiotherapy, and the molecular signaling mechanisms of anticancer compounds. Dr. Elbakary is proficient in cutting-edge molecular biology techniques, animal models, and high-throughput sequencing. She is an active member of several professional societies, including the Egyptian Society of Biochemistry and the Japan Radiation Research Society. She has served as a reviewer for high-impact journals such as Scientific Reports, Integrative Cancer Therapies, and Toxicology Reports. Her research is widely recognized for its translational value in cancer therapy and biomarker discovery. Her involvement in scientific conferences and collaborative research networks underscores her dedication to advancing biochemical and radiological sciences.

Professional Profile

Scopus

Orcid

Google Scholar

Education

Dr. Elbakary’s academic journey began with a B.Sc. in Chemistry and Biochemistry from Zagazig University in 2007, followed by a Diploma in Biochemistry in 2008 from the same institution. She pursued pre-master coursework in Biochemistry at Tanta University in 2010. Her Master’s degree in Molecular Cancer Biology was earned at the Genetic Engineering and Biotechnology Research Institute (GEBRI), Al-Sadat City University. She was awarded a Ph.D. in Biochemistry from Ain Shams University in 2017, focusing on molecular mechanisms of radiation and natural compounds in cancer biology. Throughout her education, she complemented her scientific expertise with certifications in TOEFL and ICDL and participated in over 30 specialized training programs, including advanced biostatistics, genomics, research ethics, and proposal writing. Her interdisciplinary training spans classical biochemistry, molecular therapeutics, and modern analytical techniques such as CRISPR, proteomics, and molecular docking, positioning her at the forefront of radiation biology and translational medicine.

Experience

Dr. Elbakary began her research career as an MSc scholar at the Atomic Energy Authority, supported by the Academy of Scientific Research and Technology (ASRT). From 2011 to 2018, she served as a demonstrator of Chemistry at Science Valley Academy. She then progressed through several academic ranks at NCRRT, including Biochemistry Specialist (2012–2014), Assistant Lecturer (2014–2017), Lecturer (2017–2022), and currently as Associate Professor (since 2023). She has mentored multiple Ph.D. and Master’s theses, notably in experimental therapeutics for hepatocellular and colon carcinoma. Dr. Elbakary’s technical proficiencies encompass in vivo cancer models, flow cytometry, Western blotting, ELISA, CRISPR gene editing, and data science using R and SPSS. Her teaching and lab supervision have shaped aspiring biochemists and researchers, while her collaborations with institutions like Cairo University and Al-Azhar University emphasize her leadership in academic research. She is actively involved in scientific outreach and healthcare campaigns, including national screenings and community health programs.

Research Interests

Dr. Elbakary’s research lies at the intersection of cancer biology, radiation therapeutics, and molecular pharmacology. She is particularly interested in how low-dose gamma radiation influences cancer cell pathways, and how natural compounds like resveratrol, ashwagandha, prodigiosin, and fucoxanthin enhance radiosensitivity and inhibit tumor progression. Her expertise spans apoptosis, inflammation, signal transduction, and epigenetic regulation. She has investigated the MAPK/TNF-α/NLRP3, JAK/STAT3, and β-Catenin/NOTCH pathways, as well as the impact of CRISPR-based interventions in oncology. Additionally, she is engaged in bioinformatics, studying transcriptomics, TCGA data, and biomarker validation using tools like GSEA and molecular docking. Dr. Elbakary also delves into nanoparticle-based drug delivery systems and bacterial therapies, aiming to develop safer, more effective anti-cancer treatments. Her multidisciplinary research integrates laboratory experimentation with computational modeling, making significant contributions to translational cancer therapeutics and personalized medicine. Her goal remains clear: advancing cancer treatment strategies that combine precision biology with biotechnological innovation.

Awards

Dr. Elbakary has received multiple recognitions throughout her career. Her early achievements include a prestigious scholarship for her MSc studies from the Academy of Scientific Research and Technology (ASRT). She was awarded the “Scientists for the Next Generation” training program, which provided foundational skills in grant writing, lab safety, and biostatistics. She was a featured guest editor for Archive and Case Report Journal and has served as a reviewer for prominent scientific journals, including Scientific Reports, Biomed Research International, Integrative Cancer Therapies, and Human and Experimental Toxicology. In addition to her academic accolades, Dr. Elbakary has been an invited speaker and attendee at over 40 national and international conferences, including the BGICC, AASD, and SESAME. Her voluntary participation in national health initiatives, such as Egypt’s HCV and non-communicable diseases screening campaigns, underscores her commitment to public health. She is a member of multiple scientific societies, including the Japan Radiation Research Society and WiN Egypt.

Top Noted Publications

Title: Role of bee venom and melittin on restraining angiogenesis and metastasis in γ-irradiated solid Ehrlich carcinoma-bearing mice
Year: 2020
Cited by: 52

Title: Antitumor and radiosensitizing synergistic effects of apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice
Year: 2017
Cited by: 33

Title: Gamma radiation-attenuated Toxoplasma gondii provokes apoptosis in Ehrlich ascites carcinoma-bearing mice generating long-lasting immunity
Year: 2020
Cited by: 30

Title: Pomegranate peel extract sensitizes hepatocellular carcinoma cells to ionizing radiation, induces apoptosis and inhibits MAPK, JAK/STAT3, β-catenin/NOTCH, and SOCS3 signaling
Year: 2023
Cited by: 19

Title: Withania somnifera (Ashwagandha) root extract counteracts acute and chronic impact of γ-radiation on liver and spleen of rats
Year: 2022
Cited by: 18

Title: Pro-apoptotic and anti-neoplastic impact of luteolin on solid Ehrlich carcinoma-bearing mice exposed to gamma radiation
Year: 2020
Cited by: 18

Conclusion

With her deep research expertise, rich publication record, mentoring roles, and commitment to advancing cancer therapeutics and radiation biology, Dr. Nermeen Elbakary stands as a highly commendable candidate for the Best Researcher Award. Her contributions significantly advance the field, making her a strong representative of innovation and leadership in medical and biochemical sciences.

Dr. Boris Skryabin | Biochemistry | Best Paper Award

Published on by Environmental Scientists

Dr. Boris Skryabin | Biochemistry | Best Paper Award

Dr. Boris Skryabin, Head of the Transgenic animal and genetic engineering Models (TRAM), Faculty of Medicine of the Muenster University, Germany

Dr. Boris Skryabin, born on September 23, 1960, in Riga, Latvia, is a distinguished scientist with a profound background in molecular genetics. He has made significant contributions to the field through his extensive research and leadership, particularly in transgenic animal models and genetic engineering. Dr. Skryabin currently serves as the Head of the Transgenic Animal and Genetic Engineering Models (TRAM) facility at WWU Muenster, where he continues to push the boundaries of genetic research.

🌟📋Profile

Orcid

Dr. Boris Skryabin’s qualifications and achievements suggest he is highly suitable for the “Best Paper Award” research. Here’s a detailed assessment based on the strengths and areas for improvement, followed by a conclusion:

💪🏆✨Strengths for the Award

Extensive Publication Record: Dr. Skryabin has an extensive list of peer-reviewed publications spanning over three decades. His work covers a wide range of topics including molecular genetics, neurobiology, and genetic engineering. This breadth of research indicates a strong, diverse expertise and significant contributions to multiple fields.

Impactful Research Contributions: His studies have addressed important areas such as the genetic basis of diseases (e.g., phenylketonuria), innovative methods in DNA amplification, and the role of non-coding RNAs in neuronal function. Publications in high-impact journals like Nature, Science, and JBC highlight the significance and quality of his work.

Leadership and Innovation: Dr. Skryabin has led major research facilities, including the Transgenic Animal and Genetic Engineering Models (TRAM) facility at WWU Muenster. His leadership role in developing advanced genetic models and techniques underscores his ability to drive innovation in his field.

International Collaboration: His postdoctoral training and collaborative work with notable institutions like The Mount Sinai Medical Center and WWU Muenster demonstrate his ability to work effectively within global research networks.

Research Methodology: Dr. Skryabin’s publications showcase a range of methodologies, including advanced genetic engineering techniques, which contribute to the advancement of the field. His work on TALEN-based systems and the manipulation of early mouse embryos exemplifies his methodological expertise.

🚀📈🔧Areas for Improvement

Interdisciplinary Integration: While Dr. Skryabin’s research is extensive, integrating findings across different fields more explicitly could enhance the application of his work. For instance, linking his genetic studies more directly with clinical outcomes or therapeutic developments might broaden the impact of his research.

Communication of Findings: Although his research is published in numerous journals, ensuring that findings are communicated effectively to both the scientific community and the public could increase the broader impact of his work. This could involve more interdisciplinary reviews or public engagement initiatives.

Focus on Emerging Trends: Keeping pace with emerging trends in molecular genetics and biomedicine, such as CRISPR technology and personalized medicine, could further enhance the relevance of his research. Regular updates in these areas might contribute to ongoing advancements and applications.

📚 Education

Dr. Skryabin began his academic journey at the Latvian Medical Academy, where he completed his undergraduate studies in medicine and earned his M.D. in 1983. He further pursued graduate studies in Molecular Genetics at the Brain Research Institute of the USSR Academy of Medical Sciences, Moscow, earning his Ph.D. in 1988. His education laid a solid foundation for his future research endeavors in molecular genetics and transgenic technologies.

💼 Experience 

Dr. Skryabin’s professional journey is marked by significant postdoctoral training and leadership roles. From 1988 to 1991, he conducted postdoctoral research at the Department of Mother’s and Child’s Health of Latvian Medical Academy. He further enhanced his expertise through training in prestigious laboratories in the USA, including the Mount Sinai Medical Center, New York. Since 1996, Dr. Skryabin has led research teams at the Institute of Experimental Pathology, WWU Muenster, and currently heads the TRAM facility, where he oversees advanced genetic engineering projects.

🔬 Research Interest

Dr. Skryabin’s research interests lie at the intersection of molecular genetics and transgenic technologies. He has a particular focus on the development and use of transgenic animal models to understand complex genetic mechanisms. His work has significantly contributed to our understanding of gene regulation, neuronal RNA, and genetic mutations, positioning him as a leading expert in his field.

🏆 Awards

Throughout his illustrious career, Dr. Skryabin has been recognized for his groundbreaking work in molecular genetics and genetic engineering. His innovative contributions to the field have earned him accolades and respect within the scientific community, further solidifying his reputation as a pioneer in transgenic research.

📝 Publications Top Notes

Advancing 3Rs: The Mouse Estrus Detector (MED) as a Low-Stress, Painless, and Efficient Tool for Estrus Determination in Mice

Advancing 3Rs: The Mouse Estrus Detector (MED) as a Low-Stress, Painless, and Efficient Tool for Estrus Determination in Mice

A Carboxy-terminal Smarcb1 Point Mutation Induces Hydrocephalus Formation and Affects AP-1 and Neuronal Signalling Pathways in Mice

CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms

Reference Genes across Nine Brain Areas of Wild Type and Prader-Willi Syndrome Mice: Assessing Differences in Igfbp7, Pcsk1, Nhlh2 and Nlgn3 Expression

Knock-in genome targeting risks: comprehensive analysis is essential for precision chromosome-editing identification

Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia

Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia

SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.

A Comprehensive Review of Genetically Engineered Mouse Models for Prader-Willi Syndrome Research.

✨🔍 Conclusion

Dr. Boris Skryabin is an excellent candidate for the “Best Paper Award” based on his substantial contributions to genetic research, innovative methodologies, and leadership in the field. His extensive publication record and significant research impact demonstrate his expertise and commitment to advancing science. Addressing the areas for improvement, such as enhancing interdisciplinary integration and communication, could further elevate the impact of his future work. Overall, his achievements reflect a distinguished career and a strong foundation for recognition with this award.